Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency

31 Jan 2025

Abstract excerpt

Inhibition of the deubiquitinating enzyme USP1 can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD) and represents a novel therapeutic strategy for the treatment of BRCA1/2-mutant cancers, potentially including patients whose tumors have primary or acquired resistance to PARP inhibitors (PARPi). In this study, we present a comprehensive characterization of TNG348, an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Radiation Therapy and Dosimetry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39886906
DOI: 10.1158/1535-7163.mct-24-0515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyPMID 39886906Read ↗

The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.Semantic proximity Read ↗

Targeting DNA damage response pathways in cancer.Semantic proximity Read ↗

Comprehensive Interrogation of Synthetic Relationships in the Human DNA Damage ResponseSemantic proximity Read ↗

FANCA Deficiency Induces Oncogenic R-Loop Dependent Synthetic Lethality with PARP1 InhibitorsSemantic proximity Read ↗

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discoverySemantic proximity Read ↗

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.Semantic proximity Read ↗

USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cellsSemantic proximity Read ↗

USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand BreaksSemantic proximity Read ↗

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.Semantic proximity Read ↗

Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degraderSemantic proximity Read ↗

Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging ChemotherapeuticsSemantic proximity Read ↗

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.